JP7410574B2 - 小陰唇皮膚治療用の皮膚軟膏 - Google Patents
小陰唇皮膚治療用の皮膚軟膏 Download PDFInfo
- Publication number
- JP7410574B2 JP7410574B2 JP2020560469A JP2020560469A JP7410574B2 JP 7410574 B2 JP7410574 B2 JP 7410574B2 JP 2020560469 A JP2020560469 A JP 2020560469A JP 2020560469 A JP2020560469 A JP 2020560469A JP 7410574 B2 JP7410574 B2 JP 7410574B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- ointment
- labia minora
- treating
- growth factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001313288 Labia Species 0.000 title claims description 91
- 239000002674 ointment Substances 0.000 title claims description 83
- 238000011282 treatment Methods 0.000 title description 21
- 239000003102 growth factor Substances 0.000 claims description 61
- 238000001356 surgical procedure Methods 0.000 claims description 30
- 210000003905 vulva Anatomy 0.000 claims description 18
- 208000003827 Vulvar Vestibulitis Diseases 0.000 claims description 12
- 239000005556 hormone Substances 0.000 claims description 12
- 229940088597 hormone Drugs 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 6
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 5
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 5
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 5
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 5
- 241000221095 Simmondsia Species 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 239000003270 steroid hormone Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 4
- 108060003393 Granulin Proteins 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 241001529742 Rosmarinus Species 0.000 claims description 4
- 241001530490 Salvia rosmarinus Species 0.000 claims description 4
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229960003993 chlorphenesin Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 235000015639 rosmarinus officinalis Nutrition 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229940057429 sorbitan isostearate Drugs 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 241000221096 Simmondsia chinensis Species 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 229940060184 oil ingredients Drugs 0.000 claims description 3
- 101150021185 FGF gene Proteins 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 117
- 238000011084 recovery Methods 0.000 description 12
- 206010046914 Vaginal infection Diseases 0.000 description 11
- 201000008100 Vaginitis Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 9
- 238000011069 regeneration method Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 210000003029 clitoris Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
皮膚軟膏であり、
複合成長因子(Multi Growth Factor)を有効成分として含むことをその構成上の特徴とする。
ユーザの外陰部に周期的に塗布され、外陰部前庭炎、または小陰唇手術による傷を治療することができる。
FGF、bGFG、GM-CSF、HGF、IGF-1、IL-6,7,8、KGF、Matrix proteins、PDGF-AA、TGF-B2、TGF-B3、EGF、VEGF及びTNFを含む複合成長因子でもある。
重量基準として、200,000ppm~400,000ppm濃度で、前記複合成長因子を含んでもよい。
重量基準として、300,000ppm濃度で、前記複合成長因子を含んでもよい。
精製水、グリセリン(glycerin)、ホホバシードオイル(Simmondsia chinensis(jojoba)seed oil)、キサンタンガム(Xanthan gum)、ヒドロキシエチルアクリレート/ナトリウムアクリロイルジメチルタウレートコポリマー(hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer)、スクアレン、(squalane)、ポリソルベート60(polysorbate 60)、ローズマリー葉油(Rosmarinus officinalis(Rosemary)leaf oil)、乳酸(lactic acid)、クロルフェネシン(Chlorphenesin)及びイソステアリン酸ソルビタン(Sorbitaniso isostearate)を含み、軟膏剤形にも製造される。
女性ホルモン、環境ホルモン、ステロイドホルモン、及び抗生物質成分が除かれうる。
カリフォルニア州立大学校Irvineキャンパスに位置した組織銀行(Tissue Bank at University of California,Ivine)から給された人体線維芽細胞(包皮(foreskin)からの抽出)内から、健康に生きている線維芽細胞を選別し、全ての培養過程において、一貫した因子濃度を維持するようにし、培養液タイプに複合成長因子を生産した。生産された複合成長因子は、FGF、bGFG、GM-CSF、HGF、IGF-1、IL-6,7,8、KGF、Matrix proteins、PDGF-AA、TGF-B2、TGF-B3、EGF、VEGF及びTNFを含み、該複合成長因子、並びに精製水、グリセリン(glycerin)、ホホバシードオイル(Simmondsia chinensis (jojoba) seed oil)、キサンタンガム(Xanthan gum)、ヒドロキシエチルアクリレート/ナトリウムアクリロイルジメチルタウレートコポリマー(hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer)、スクアレン(squalane)、ポリソルベート60(polysorbate 60)、ローズマリー葉油(Rosmarinus officinalis (Rosemary) leaf oil)、乳酸(lactic acid)、クロルフェネシン(Chlorphenesin)及びイソステアリン酸ソルビタン(Sorbitan isostearate)を混合し、複合成長因子が、重量基準として、300,000ppm濃度に含有されるように、軟膏剤形の小陰唇皮膚治療用の皮膚軟膏を製造した。製造された皮膚軟膏は、15ml容量のチューブ状容器に入れた。
小陰唇及び陰核の整形術を受けた女性に、製造された15ml容量のチューブ状容器に入った小陰唇皮膚治療用の皮膚軟膏を提供し、外陰部に、1日1回周期的に塗布するようにしながら、手術後2週間、経過を観察した。
図4は、小陰唇及び陰核の整形術を受けた患者に、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗ることにより、回復された程度を観察した様子を示した写真であり、(a)は、手術前、(b)は、手術後2週が経過した時点の写真である。手術部位である右側小陰唇部位に、1日1回周期的に本発明の小陰唇皮膚治療用の皮膚軟膏を塗布した結果、2週後に大きく回復したところを確認することができる。
小陰唇肥大によって手術を受けた女性に、製造された15ml容量のチューブ状容器に入った小陰唇皮膚治療用の皮膚軟膏を提供し、外陰部に、1日1回周期的に塗布するようにしながら、手術後20日間、経過を観察した。
図5は、小陰唇肥大によって手術を受けた患者に、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗ることにより、回復された程度を観察した様子を示した写真である。上端は、手術前の写真であり、下端の(a)は、手術後4日目、(b)は、手術後1週間目、(c)は、手術後19日が経過した時点の写真である。図5の(a)、(b)及び(c)において、左側小陰唇は、一般的に、小陰唇手術後に処方されるホルモンを含んだ軟膏を塗りながら回復される様子であり(写真において、「OINT」表示)、右側小陰唇は、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗りながら回復される様子である(写真で“WMPF”表示)。図5の(a)、(b)及び(c)から確認することができるように、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗った部位の皮膚再生が、一般軟膏を塗った部位に比べ、迅速に進み、その形態回復も、さらに円滑であった。そのように、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏は、既存の一般軟膏に比べ、小陰唇手術による傷治療に著しい効果があり、形態回復にも、一助となり、小陰唇手術の満足度を向上させることができる。
外陰部前庭炎及び萎縮性膣炎の診断を受けた女性に、製造された15ml容量のチューブ状容器に入った小陰唇皮膚治療用の皮膚軟膏を提供し、外陰部に、1日1回周期的に塗布するようにしながら、48日間、経過を観察した。
図6は、外陰部前庭炎及び萎縮性膣炎の診断を受けた患者に、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗ることにより、回復された程度を観察した様子を示した写真である。図6の上端は、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏適用前の写真であり、10年前から、外陰部痛、性交痛、骨盤痛、下腹部痛、腰痛と共に、外陰部不快感や、排尿痛・頻尿・夜間尿・切迫尿のような排尿症状により、日常生活に大きい不都合さを感じる患者の外陰部を示す。該患者は、萎縮性膣炎及び外陰部前庭炎の診断下、ホルモン療法を3回ほど施行をしたにもかかわらず、治療効果が示されていない場合である。前述の患者の外陰部に、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を、1日1回周期的に塗布した後、外陰部の回復程度を観察した。
図6の下端(a)は、本発明の皮膚軟膏適用後17日、(b)は、本発明の皮膚軟膏適用後27日、(c)は、本発明の皮膚軟膏適用後48日がそれぞれ経過した時点の写真である。具体的には、図6の上端写真から確認することができるように、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を塗る前には、外陰部がはなはだしく腫れており、出血が伴う症状を示したが、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を周期的に塗った後には、図6の(a)ないし(c)から確認することができるように、外陰部の出血が止まり、本来の外陰部の色に回復されるところを確認することができる。それだけではなく、図6を介し、既存のホルモン療法のような治療を介して治療効果を得ることができなかった場合にも、本発明の一実施例による小陰唇皮膚治療用の皮膚軟膏を介し、外陰部前庭炎のような小陰唇皮膚の疾患に対し、明らかな治療効果を得ることができるということを確認することができる。
Claims (6)
- 皮膚軟膏として、
複合成長因子(Multi Growth Factor)を有効成分として含むが、
前記複合成長因子は、FGF、bFGF、GM-CSF、HGF、IGF-1、IL-6,7,8、KGF、Matrix proteins、PDGF-AA、TGF-B2、TGF-B3、EGF、VEGF及びTNFを含む複合成長因子であり、
小陰唇手術による傷を治療し、半固形の外用薬である軟膏の剤形であることを特徴とする、小陰唇皮膚治療用の皮膚軟膏。 - ユーザの外陰部に周期的に塗布され、外陰部前庭炎を治療することを特徴とする請求項1に記載の小陰唇皮膚治療用の皮膚軟膏。
- 皮膚軟膏として、
複合成長因子(Multi Growth Factor)を有効成分として含むが、
前記複合成長因子は、FGF、bFGF、GM-CSF、HGF、IGF-1、IL-6,7,8、KGF、Matrix proteins、PDGF-AA、TGF-B2、TGF-B3、EGF、VEGF及びTNFを含む複合成長因子であり、
前記複合成長因子を含む高濃度因子培養液を重量基準として、20%~40%含みながらも、半固形の外用薬である軟膏の剤形であることを特徴とする、小陰唇皮膚治療用の皮膚軟膏。 - 重量基準として、300,000ppm濃度で、前記高濃度因子培養液を含むことを特徴とする請求項3に記載の小陰唇皮膚治療用の皮膚軟膏。
- 精製水、グリセリン(glycerin)、ホホバシードオイル(Simmondsia chinensis (jojoba) seed oil)、キサンタンガム(Xanthan gum)、ヒドロキシエチルアクリレート/ナトリウムアクリロイルジメチルタウレートコポリマー(hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer)、スクアレン(squalane)、ポリソルベート60(polysorbate 60)、ローズマリー葉油(Rosmarinus officinalis (Rosemary) leaf oil)、乳酸(lactic acid)、クロルフェネシン(Chlorphenesin)及びイソステアリン酸ソルビタン(Sorbitan isostearate)を含み、軟膏剤形に製造されることを特徴とする請求項1または3に記載の小陰唇皮膚治療用の皮膚軟膏。
- 女性ホルモン、環境ホルモン、ステロイドホルモン及び抗生物質成分が除かれることを特徴とする請求項1または3に記載の小陰唇皮膚治療用の皮膚軟膏。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0086840 | 2018-07-25 | ||
KR1020180086840A KR101924894B1 (ko) | 2018-07-25 | 2018-07-25 | 소음순 피부 치료용 피부연고 |
PCT/KR2019/006065 WO2020022627A1 (ko) | 2018-07-25 | 2019-05-21 | 소음순 피부 치료용 피부연고 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021533081A JP2021533081A (ja) | 2021-12-02 |
JP7410574B2 true JP7410574B2 (ja) | 2024-01-10 |
Family
ID=64668960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020560469A Active JP7410574B2 (ja) | 2018-07-25 | 2019-05-21 | 小陰唇皮膚治療用の皮膚軟膏 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210046161A1 (ja) |
JP (1) | JP7410574B2 (ja) |
KR (1) | KR101924894B1 (ja) |
CN (1) | CN110237236A (ja) |
WO (1) | WO2020022627A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101924894B1 (ko) * | 2018-07-25 | 2018-12-04 | 베네브바이오랩 주식회사 | 소음순 피부 치료용 피부연고 |
KR102579844B1 (ko) * | 2022-10-18 | 2023-09-19 | 비엔뷔바이오랩 주식회사 | 인체 조직 재생 효과가 있는 인체 섬유아세포 배양액 복합물(g4prf-300), 이의 제조 방법 및 이를 포함하는 피부 외용 액상 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513438A (ja) | 2004-09-15 | 2008-05-01 | ネオキュティス エスアー | 皮膚の状態、障害または疾患の処置のための胎児皮膚細胞タンパク質組成物、ならびにその作製法および使用法 |
JP2014508160A (ja) | 2011-03-04 | 2014-04-03 | アル−カタニ,アーメッド・エイチ | スキンクリーム |
JP2016516023A (ja) | 2013-03-13 | 2016-06-02 | ネオキュティス エスアー | 皮膚更新のためのペプチド及び前記ペプチドを使用する方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
CA2670431C (en) * | 2006-12-11 | 2014-04-08 | The Procter & Gamble Company | Single-use personal care products and kits comprising same |
RU2012133444A (ru) * | 2010-01-06 | 2014-02-20 | Орф Лифтаекни Хф | Способ, применения стабильного фактора роста растительного происхождения в уходе за кожей |
CN101884602A (zh) * | 2010-03-03 | 2010-11-17 | 孙杰 | 一种皮肤美容修复抗衰除皱的化妆品制剂 |
US9119974B2 (en) * | 2011-03-04 | 2015-09-01 | Ahmed H. Al-Qahtani | Skin cream |
CN103182070B (zh) * | 2013-04-12 | 2014-02-12 | 江苏迪沃生物制品有限公司 | 一种外用组合物、制剂及其应用 |
CN104056258B (zh) * | 2014-06-05 | 2016-05-18 | 武汉科隆生物医学有限公司 | 促进受损组织生理调节性再生的组合物及制备方法与应用 |
KR102564239B1 (ko) * | 2014-12-03 | 2023-08-09 | 마리 케이 인코포레이티드 | 화장료 조성물 및 이를 이용하는 방법 |
ITUB20155902A1 (it) * | 2015-11-25 | 2017-05-25 | Nathura S P A | Composizione farmaceutica cicatrizzante per uso topico |
CN106075399A (zh) * | 2016-07-22 | 2016-11-09 | 简婷婷 | 用于激素性皮炎的组合物,制剂及制备方法和应用 |
KR101924894B1 (ko) * | 2018-07-25 | 2018-12-04 | 베네브바이오랩 주식회사 | 소음순 피부 치료용 피부연고 |
-
2018
- 2018-07-25 KR KR1020180086840A patent/KR101924894B1/ko active IP Right Grant
-
2019
- 2019-05-09 CN CN201910385868.0A patent/CN110237236A/zh active Pending
- 2019-05-21 WO PCT/KR2019/006065 patent/WO2020022627A1/ko active Application Filing
- 2019-05-21 US US17/051,165 patent/US20210046161A1/en active Pending
- 2019-05-21 JP JP2020560469A patent/JP7410574B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513438A (ja) | 2004-09-15 | 2008-05-01 | ネオキュティス エスアー | 皮膚の状態、障害または疾患の処置のための胎児皮膚細胞タンパク質組成物、ならびにその作製法および使用法 |
JP2014508160A (ja) | 2011-03-04 | 2014-04-03 | アル−カタニ,アーメッド・エイチ | スキンクリーム |
JP2016516023A (ja) | 2013-03-13 | 2016-06-02 | ネオキュティス エスアー | 皮膚更新のためのペプチド及び前記ペプチドを使用する方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2020022627A1 (ko) | 2020-01-30 |
KR101924894B1 (ko) | 2018-12-04 |
JP2021533081A (ja) | 2021-12-02 |
US20210046161A1 (en) | 2021-02-18 |
CN110237236A (zh) | 2019-09-17 |
WO2020022627A8 (ko) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101209267B (zh) | 红色诺卡氏菌细胞壁骨架在制备治疗皮肤损伤和疮疡的药物中的用途 | |
CN107456509B (zh) | 一种用于女性阴道预防、保健以及治疗妇科生殖道炎症的外用生物制剂以及制备方法 | |
JP7410574B2 (ja) | 小陰唇皮膚治療用の皮膚軟膏 | |
WO2020135476A1 (zh) | 一种中药组合物及其制备方法和应用 | |
CN102335223B (zh) | 一种治疗人乳头瘤病毒感染症的中药制剂及其制备方法和应用 | |
CN102895524A (zh) | 一种治疗妇科炎症的组合药物 | |
CN102274380B (zh) | 治疗烧、烫伤的外用药 | |
CN104721489A (zh) | 一种治疗帕金森症的中成药及其制备方法 | |
CN108524684A (zh) | 裸花紫珠中具有抗宫颈炎作用的活性部位筛选 | |
CN101057823B (zh) | 一种具有抗衰老及美容作用的复合生物制剂 | |
CN101797371B (zh) | 一种用于减肥按摩的药物组合物 | |
CN105012702A (zh) | 外用生肤油在制备预防或治疗糖尿病性末梢循环障碍及足溃疡的药物中的应用 | |
CN105168625B (zh) | 一种临床护理上用于治疗二、三期褥疮的中药涂膜剂 | |
CN104257898B (zh) | 一种治疗产后月经不调的中药制剂 | |
CN102697855A (zh) | 治疗皮肤疾病的药物组合物 | |
CN114259555B (zh) | 一种中西医结合复合制剂及其应用 | |
CN103536706B (zh) | 一种治疗妊娠期念珠菌性阴道炎的中药薰洗剂 | |
Davood et al. | Avicenna’s views on factors affecting wound healing | |
CN1330371C (zh) | 一种重组人表皮生长因子复合生物制剂及其应用 | |
RU2080869C1 (ru) | Способ лечения заболеваний натуральными соками лекарственных растений | |
CN105168632A (zh) | 一种促进剖宫产伤口愈合的中药涂膜剂及其制备方法 | |
Htinashyal | A Clinical Study of Effects of Chaturbeeja Churna in Sutika Paricharya Wsr Katishoola | |
CN108066570B (zh) | 痔疮手术后消炎止痛的中药提取物及其应用 | |
CN105168633A (zh) | 金女带清白敷脐剂 | |
CN104547989A (zh) | 一种用于治疗脊椎病的藏药膏剂及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211013 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7410574 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |